by : Matthew Herper, 07.30.07, 6:17 PM ETE-mail: mherper@forbes.com
A panel of advisers to the Food and Drug Administration voted overwhelmingly that Avandia, the controversial diabetes pill from drug maker GlaxoSmithKline, should stay on the market.
But the panel of scientists were also in broad agreement that the drug does cause an increase in the risk of heart attacks, with some of them recommending that the FDA take some of the strongest steps in its power to limit use of the drug. The FDA is not compelled to follow the advice of its committees, but it usually does.
But the panel of scientists were also in broad agreement that the drug does cause an increase in the risk of heart attacks, with some of them recommending that the FDA take some of the strongest steps in its power to limit use of the drug. The FDA is not compelled to follow the advice of its committees, but it usually does.
No comments:
Post a Comment